Teva Jumps as New CEO Jeremy Levin Set to Give Guidance Update

Teva Pharmaceutical Industries Ltd. (TEVA) rose the most in almost two months before new Chief Executive Officer Jeremy Levin gives an update on financial guidance.

The stock of the world’s largest generic drugmaker jumped the most since April 1, adding 2.4 percent to 153 shekels at 2:36 p.m. in Tel Aviv.

To contact the reporter on this story: David Wainer in Tel Aviv at dwainer3@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.